Status and phase
Conditions
Treatments
About
To establish the optimum injection rate for E7337 (Iomeron 350) in dynamic CT in patients who have hepatic lesions.The primary endpoint for efficacy is the contrast enhancement effect in the early arterial phase, and the primary safety endpoints are warming sensation and vascular pain.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteira:
Exclusion Criteria
Items that may affect the safety evaluation of E7337
General concerns relating to the safety of the subject.
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal